Reuters logo
7 months ago
BRIEF-Kiadis Pharma issues clinical and regulatory progress update on ATIR101 and ATIR201
February 6, 2017 / 6:11 AM / 7 months ago

BRIEF-Kiadis Pharma issues clinical and regulatory progress update on ATIR101 and ATIR201

Feb 6 (Reuters) - Kiadis Pharma NV :

* Kiadis Pharma issues clinical and regulatory progress update on ATIR101 and ATIR20

* Announce initiation of its randomized, controlled, transatlantic phase III trial with ATIR101 (CR-AIR-009)

* Approximately 195 patients with acute leukemia will be enrolled in total in phase III trial

* Patients to receive a haploidentical allogeneic HSCT using either Kiadis Pharma approach with a single dose of ATIR101 or post-transplant cyclophosphamide approach

* Ongoing CR-AIR-008 trial continues to confirm safety profile of ATIR101

* Contingent on approval from EMA, Kiadis Pharma anticipates launching ATIR101(tm) in to European market in 2018

* Kiadis Pharma expects first clinical trial data of ATIR201 to become available in the second half of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below